Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia

Leuk Res. 2020 Feb:89:106297. doi: 10.1016/j.leukres.2020.106297. Epub 2020 Jan 7.

Affiliations

¹ Department of Internal Medicine, The Ohio State University, Columbus, OH, 43210, United States. Electronic address: Caner.Saygin@osumc.edu.
² Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, United States.
³ Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, United States. Electronic address: Alice.Mims@osumc.edu.

PMID: 31935625
DOI: 10.1016/j.leukres.2020.106297

No abstract available

Publication types

Letter

MeSH terms

Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use*
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality*
Prednisone / adverse effects
Prednisone / therapeutic use*
Prognosis
Rituximab / adverse effects
Rituximab / therapeutic use*
Treatment Outcome
Vincristine / adverse effects
Vincristine / therapeutic use*

Substances

R-CVP protocol
Rituximab
Vincristine
Cyclophosphamide
Prednisone

Supplementary concepts

COP protocol 2